Policies related to Medicare reimbursement for cancer diagnostics.
2026 · 1st Quarter (Jan 1 - Mar 31)
PRELUDE CORPORATION (PRELUDEDX)
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $70,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- f78a5bdd-0ebb-4017-8639-55a3d03e55cf
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Improved patient access to cancer screening diagnostics.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.